Stock Pick

Pro Medicus shares crash 20% on results day

Written by

openjargon

in

A man holds his head in his hands, despairing at the bad result he's reading on his computer.

Pro Medicus Ltd (ASX: PME) shares are having a day to forget on Thursday.

In morning trade, the health imaging technology company’s shares are down almost 20% to $136.75.

This follows the release of the company’s half-year results.

Pro Medicus shares crash on results day

For the six months ended 31 December, Pro Medicus reported a 28.4% increase in revenue to $124.8 million. This was underpinned by six key implementations in the half, all of which are cloud-based.

Pro Medicus’ underlying EBIT margin increased to 73% from 72% a year earlier. This underlying a 29.7% lift in underlying profit before tax to a record of $90.7 million.

Reported net profit after tax came in at $171.2 million, which is up 230.9% on the prior corresponding period. This reflects unrealised gains from its investment in 4DMedical Ltd (ASX: 4DX).

Commenting on the company’s performance, CEO Dr Sam Hupert said:

Our profits continue to grow strongly even though our biggest implementation during the period in Trinity Cohort 1 went live towards the end of October so had limited impact on the half. Importantly, our margins also grew, and we made more sales in this half than we used to make in a full year just 2 years ago. Most contracts were for the full stack of Visage products – Viewer, Workflow and Archive and two also included our cardiology offering making them full stack +1, a trend we see continuing.

What about the AI threat?

In an accompanying interview, Dr Hupert spoke at length about the threat of AI on the company’s business.

The good news is that he doesn’t believe its Visage software is going to be replaced by AI. He explains:

The second concern is a belief held by some that new AI tools will radically disrupt software development with Vibe coding helping destroy the “IP moat” of all software and SaaS providers. They claim anyone will be able to use AI tools to write industry grade software in a fraction of the time.

This, in our view, is an overly simplistic generalisation, one that certainly doesn’t apply to us. Visage 7 was built from the ground up using our own proprietary technology. It is not based on some readily available tool kit or platform. It is a very specialised, highly technical, patented suite of software that incorporates more than 30 years of domain knowledge; it is not a product that can be readily replicated with or without AI. We have not left a roadmap for others to follow.

The post Pro Medicus shares crash 20% on results day appeared first on The Motley Fool Australia.

Should you invest $1,000 in 4DMedical Limited right now?

Before you buy 4DMedical Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 1 Jan 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts